The Myc/Max/Mad network and the transcriptional control of cell behavior

Annual Review of Cell and Developmental Biology

Volumn 16, Issue , 2000, Pages 653-699

  Grandori, C ^a   Cowley, S M ^a   James, L P ^a   Eisenman, R N ^a  

^a USA   (United States)

Author keywords

Cell cycle; Oncogene; Repression; Transcription

Indexed keywords

MAX PROTEIN; PROTEIN; PROTEIN MGA; PROTEIN MNT; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MAD; TRANSCRIPTION FACTOR MYC; UNCLASSIFIED DRUG;

ANGIOGENESIS; CELL ADHESION; CELL CYCLE; CELL FUNCTION; CELL GROWTH; CHROMATIN STRUCTURE; GENE CONTROL; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION REGULATION;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; DNA-BINDING PROTEINS; HELIX-LOOP-HELIX MOTIFS; HUMANS; ONCOGENE PROTEIN P55(V-MYC); PROTO-ONCOGENE PROTEINS C-MYC; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS;

EID: 0034524132     PISSN: 10810706     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.cellbio.16.1.653     Document Type: Review

References (297)

1. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression
2. Oncogenic activity of the c-Myc protein requires dimerization with Max
3. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max
4. Myc-Max-Mad: A transcription factor network controlling cell cycle progression, differentiation and death
5. The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max
6. Myc suppresses induction of the growth arrest genes gadd34, gadd45, and gadd153 by DNA-damaging agents
7. Functional role for c-myc in mitogenic response to platelet-derived growth factor
8. Transcription of chromatin: These are complex times
9. Constitutive c-myc expression in IL-3 dependent myeloid cell line suppresses cycle arrest and accelerates apoptosis
10. Myc and Max: Molecular evolution of a family of proto-oncogene products and their dimerization partner
11. Yy1 can inhibit c-myc function through a mechanism requiring DNA binding of yy1 but neither its trans-activation domain nor direct interaction with c-myc
12. A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation
13. Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity
14. Mad proteins contain a dominant transcription repression domain
15. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3
16. Myc but not Fos rescue of a PDGF signalling block by kinase-inactive Src
17. 1 integrin with the altered cell: Environmental interactions and enhanced soft agar cloning ability of c-myc-overexpressing small cell lung cancer cells
18. C-myc suppresses the tumorigenicity of lung cancer cells and down-regulates vascular endothelial growth factor expression
19. mxi1 tumor suppressor gene is not mutated in primary pancreatic adenocarcinoma
20. The ornithine decarboxylase gene is a transcriptional target of c-myc
21. An embryonically expressed gene is a target for c-Myc regulation via the c-Myc-binding sequence
22. Max encodes a sequence-specific DNA binding protein and is not regulated by serum growth factors
23. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas
24. Mlx, a novel Max-like BHLHZip protein that interacts with the Max network of transcription factors
25. A transfected L-myc gene can substitute for c-myc in blocking murine erythroleukemia differentiation
26. Apoptotic cell death induced by c-myc is inhibited by bcl-2
27. Binding of Myc proteins to canonical and noncanonical DNA sequences
28. Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA binding complex with Myc
29. Myc and Max associate in vivo
30. Functional analysis of the AUG- and CUG-initiated forms of the c-Myc protein
31. Control of cell proliferation by myc
32. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27
33. Coexamination of site-specific transcription factor binding and promoter activity in living cells
34. Identification of target genes of oncogenic transcription factors
35. c-Myc target gene specificity is determined by a post-DNA-binding mechanism
36. Angiogenesis is an early event in the generation of myc-induced lymphomas
37. An essential domain of the c-Myc protein interacts with a nuclear factor that is also required for E1A-mediated transformation
38. The crystal structure of an intact human Max-DNA complex: New insights into mechanisms of transcriptional control
39. c-myc null cells mis-regulate cad and gadd45 but not other proposed c-Myc targets
40. WAF1 transduction in K562 leukemia cells
41. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins
42. The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals
43. Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene
44. FH3, a v-myc avian retrovirus with limited transforming ability
45. Effects of the MYC oncogene antagonist MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumor cells
46. c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for activation function
47. Essential role for oncogenic ras in tumour maintenance
48. Degradation of nuclear oncoproteins by the ubiquitin system in vitro
49. The myc oncogene: Its role in transformation and differentiation
50. The myc oncoprotein: A critical evaluation of transactivation and target gene regulation
51. Expression analysis with oligonucleotide microarrays reveals MYC regulates genes involved in growth, cell cycle, signaling, and adhesion
52. Constitutive c-myc oncogene expression blocks mouse erythroleukemia cell differentiation but not commitment
53. Activation of cellular oncogenes in hematopoietic cells by chromosome translocation
54. Transgenic mice and oncogenesis
55. C-myc gene expression is stimulated by agents that activate protein kinase c and does not account for the mitogenic effect of PDGF
56. Altered cytoplasmic/nuclear distribution of the c-myc protein in differentiating ML-1 human myeloid leukemia cells
57. Gene-regulatory properties of Myc helixloop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity
58. The leucine zipper domain of avian c-Myc is required for transformation and autoregulation
59. Function of the c-Myc antagonist Mad1 during a molecular switch from proliferation to differentiation
60. c-Myc target genes involved in cell growth, apoptosis, and metabolism
61. Discrimination between related DNA sites by a single amino acid residue of Myc-related basic-helix-loop-helix proteins
62. Mutation of N-myc in mice: What does the phenotype tell us?
63. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygous and reduced fertility in heterozygous female mice
64. The MyoD DNA binding domain contains a recognition code for muscle-specific gene activation
65. Acquisition of myogenic specificity by replacement of three amino acid residues from MyoD into E12
66. myc family oncogenes in the development of normal and neoplastic cells
67. Discrimination between different E-box-binding proteins at an endogenous target gene of c-myc
68. Contrasting patterns of myc and N-myc expression during gastrulation of the mouse embryo
69. Molecular bases for circadian clocks
70. Mutation of the MXI1 gene in prostate cancer
71. Mapping of two genes encoding members of a distinct subfamily of MAX interacting proteins: MAD to human chromosome 2 and mouse chromosome 6, and MXI1 to human chromosome 10 and mouse chromosome 19
72. No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters
73. A 13-amino acid amphipathic alpha-helix is required for the functional interaction between the transcriptional repressor Mad1 and mSin3a
74. Chimeras of Myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells
75. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
76. Induction of apoptosis in fibroblasts by c-myc protein
77. The molecular role of myc in growth and transformation: Recent discoveries lead to new insights
78. Cooperative interaction between c-myc and bcl-2 proto-oncogenes
79. Reversible tumorigenesis by MYC in hematopoietic lineages
80. Transient excess of MYC activity can elicit genomic instability and tumorigenesis
81. Structure and function of the b/HLH/Z domain of USF
82. Recognition of Max by its cognate DNA through a dimeric b/HLH/Z domain
83. Transcription activation by myc and max: Flanking sequences target activation to a subset of cacgtg motifs in vivo
84. Differential effects of the widely expressed dMax splice variant of Max on E-box vs initiator element-mediated regulation by c-Myc
85. Myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome
86. Two Mad tails: What the recent knockouts of Mad1 and Mxi1 tell us about the MYC/MAX/MAD network
87. Targeted disruption of Mad1 inhibits cell cycle exit during granulocyte differentiation
88. 1
89. Definition of the activities and properties of c-myc required to inhibit cell differentiation
90. p53 mutations in human lymphoid malignancies: Association with Burkitt's lymphoma and chronic lymphocytic leukemia
91. Cdc25 cell-cycle phosphatase as a target of c-myc
92. Myc and Max homologs in Drosophila
93. Changes in expression of members of the fos and jun families and myc network during normal terminal differentiation of keratinocytes
94. c-Myc promotes differentiation of human epidermal stem cells
95. Transcriptional activation by Myc is under negative control by the transcription factor AP-2
96. An E-box element localized in the first intron mediates regulation of the prothymosin a gene by c-Myc
97. Protein stabilization: A common consequence of mutations in independently derived v-myc alleles
98. Overview of matrix metalloproteinase expression in cultured human cells
99. Myc target genes
100. Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo
101. Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones: Characterization of an Ada complex and the SAGA (Spt/Ada) complex
102. Myc induces the nucleolin and BN51 genes: Possible implications in ribosome biogenesis
103. Short dysfunctional telomeres impair tumorigenesis in the INK4a(δ2/3) cancer-prone mouse
104. Basal and human papillomavirus E6 oncoprotein-induced degradation of myc proteins by the ubiquitin pathway
105. Three proteins define a class of human histone deacetylases related to yeast Hda1p
106. Histone acetylation in chromatin structure and transcription
107. Binding and suppression of the Myc transcriptional activation domain by p107
108. Opposite regulation of gene transcription and cell proliferation by c-Myc and Max
109. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain
110. Mmip1: A novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc
111. Transactivation of gene expression by Myc is inhibited by mutation at the phosphorylation sites Thr-58 and Ser-62
112. Is c-Myc protein directly involved in DNA replication?
113. Creation of human tumour cells with defined genetic elements
114. Determination of the c-MYC DNA-binding site
115. Proteins encoded by the human c-myc oncogene: Differential expression in neoplastic cells
116. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines
117. The Eμ-myc transgenic mouse: A model for high-incidence spontaneous lymphoma and leukemia of early B cells
118. From molecular to modular cell biology
119. Histone deacetylase activity is required for full transcriptional repression by mSin3A
120. Expression and activity of L-myc in normal mouse development
121. Avian leukosis viruses: Activation of cellular oncogenes
122. Proteins of the Myc network: Essential regulators of cell growth and differentiation
123. Mediation of c-Myc-induced apoptosis by p53
124. Identification of CDK4 as a target of c-MYC
125. A comparative analysis of N-myc and c-myc expression and cellular proliferation in mouse organogenesis
126. Role of telomerase in cellular proliferation and cancer
127. Traps to catch unwary oncogenes
128. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis
129. Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis
130. Mnt, a novel Max-interacting protein, is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites
131. Mad3 and Mad4: Novel Max-interacting transcriptional repressors that suppress c-Myc-dependent transformation and are expressed during neural and epidermal differentiation
132. Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif
133. Possible function of the c-myc product: Promotion of cellular DNA replication
134. Down-regulation of LFA-1 adhesion receptors by c-myc oncogene in human B lymphoblastoid cells
135. c-Myc enhances protein synthesis and cell size during B lymphocyte development
136. The c-myc protooncogene regulates cardiac development in transgenic mice
137. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc induced apoptosis via INK4a/ARF
138. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus
139. Identification of eukaryotic mRNAs that are translated at reduced cap binding complex eIF4F concentrations using a cDNA microarray
140. Drosophila myc regulates growth during development
141. An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc
142. Retroviral insertional mutagenesis as a strategy to identify cancer genes
143. c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release
144. Repression by UME6 involves recruitment of a complex containing Sin3 corepressor and Rpd3 histone deacetylase to target promoters
145. Regulation of cell cycle duration by c-myc levels
146. SIN3-dependent transcriptional repression by interaction with the Mad1 DNA-binding protein
147. An amino-terminal c-Myc domain required for neoplastic transformation activates transcription
148. Max: Functional domains and interaction with c-Myc
149. dMi-2, a Hunchback-interacting protein that functions in Polycomb repression
150. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor
151. INK4a inactivation and telomerase activity are required to immortalize human epithelial cells
152. Sin meets NuRD and other tails of repression
153. Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes
154. Expression of transcriptional repressor protein mSin3A but not mSin3B is induced during neuronal apoptosis
155. Repression of Myc-Ras co-transformation by Mad is mediated by multiple protein-protein interactions
156. The Myc and Max proteins possess distinct transcriptional activities
157. The ribonucleotide reductase r2 gene is a nontranscribed target of c-myc-induced genomic instability
158. Histone deacetylases associated with the mSin3 corepressor mediate Mad transcriptional repression
159. Suppression of Myc, but not E1a, transformation activity by Max-associated proteins, Mad and Mxi1
160. Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease
161. Interaction with normal cells suppresses the transformed phenotype of v-myc transformed quail muscle cells
162. Phorbol ester-induced terminal differentiation is inhibited in human U937 cells expressing a v-Myc oncogene
163. Expression of mad, mxi1, max, and c-myc during induced differentiation of hematopoietic cells: Opposite regulation of mad and c-myc
164. Translocations among antibody genes in human cancer
165. Myc represses transcription of the growth arrest gene gas1
166. Mxi1 is a repressor of the c-myc promoter and reverses activation by usf
167. Genetic instabilities in human cancers
168. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F
169. c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II
170. c-Myc overexpression uncouples DNA replication from mitosis
171. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins
172. Proteins encoded by the c-myc oncogene: Analysis of cmyc protein degradation
173. c-myc and cmyb protein degradation: Effect of metabolic inhibitors and heat shock
174. Expression of Mad, an antagonist of Myc oncoprotein function, in differentiating keratinocytes during tumorigenesis of the skin
175. The pathogenesis of Burkitt's lymphoma
176. c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines
177. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation
178. A human Spt3-Tafii31-Gcn5-1 acetylase complex distinct from transcription factor IID
179. Phenotypes of c-myc-deficient rat fibroblasts isolated by targeted homologous recombination
180. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points
181. The Max transcription factor network: Mad1 inhibition of cell cycle progression is inhibited by the human papilloma virus E7 protein
182. The Mad protein family links transcriptional repression to cell differentiation
183. Progression from lymphoid hyperplasia to highgrade malignant lymphoma in mice transgenic for the t(14; 18)
184. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins
185. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc
186. Large induction of c-Myc is not essential for the mitogenic response of Swiss 3T3 fibroblasts
187. Multiple signals converging on NFκB
188. Rox, a novel bHLHZip protein expressed in quiescent cells that heterodimerizes with Max, binds a non-canonical E box and acts as a transcriptional repressor
189. c-myc inhibition of MyoD and myogenin-initiated myogenic differentiation
190. A targeted mutation reveals a role for N-myc in branching morphogenesis in the embryonic mouse lung
191. Defects in heart and lung development in compound heterozygotes for two different targeted mutations at the N-myc locus
192. Do products of the myc proto-oncogene play a role in transcriptional regulation of the prothymosin a gene?
193. Use of transgenic mice to study myc family gene function in normal mammalian development and in cancer
194. Interleukin-7 induces N-myc and c-myc expression in normal precursor B lymphocytes
195. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless MyoD, and myc proteins
196. Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence
197. Myc-induced cyclin d2 genomic instability in murine B cell neoplasms
198. Dissecting the role of N-myc in development using a single targeting vector to generate a series of alleles
199. MYC oncogenes and human neoplastic disease
200. Coordination of growth and cell division in the Drosophila wing
201. Connections between growth and the cell cycle
202. An in vivo function for the transforming Myc protein: Elicitation of the angiogenic phenotype
203. Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor
204. Genetarget recognition among members of the Myc superfamily and implications for oncogenesis
205. 1 in mammalian fibroblasts
206. Omithine decarboxylase is a mediator of c-Myc-induced apoptosis
207. c-Myc and apoptosis
208. When checkpoints fail
209. Reversible activation of c-Myc in skin: Induction of a complex neoplastic phenotype by a single oncogenic lesion
210. Negative autoregulation of c-myc transcription
211. CIP1
212. KIP1 binding to newly formed complexes
213. An alternative pathway for gene regulation by Myc
214. Repression of cyclin D1: A novel function of Myc
215. Transforming growth factor β1 suppression of c-myc gene transcription: Role in inhibition of keratinocyte proliferation
216. Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and Ras cotransformation
217. Methylationsensitive sequence-specific DNA binding by the c-Myc basic region
218. Commonly occurring loss and mutation of the MXI1 gene in prostate cancer
219. Analysis of Myc/Max/Mad network members in adipogenesis: Inhibition of the proliferative burst and differentiation by ectopically expressed Mad1
220. Activation of c-Myc uncouples DNA replication from activation of G1-cyclin-dependent kinases
221. Sequential expression of the MAD family of transcriptional repressors during differentiation
222. Dwarfism and dysregulated proliferation in mice overexpressing the MYC antagonist MAD1
223. Regulation of c-myc expression by IFN-γ through Stat1-dependent and -independent pathways
224. Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression domain of the Myc antagonist Mxi1
225. Immortalization and controlled in vitro differentiation of murine multipotent neural crest stem cells
226. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2a in response to growth induction by c-myc
227. Inhibition of cell proliferation by the Mad1 transcriptional repressor
228. Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signalling
229. Direct role for Myc in transcription initiation mediated by interactions with TFII-I
230. New Mycinteracting proteins: A second Myc network emerges
231. Tra1p is a component of the yeast Ada.Spt transcriptional regulatory complexes
232. Destruction of myc by ubiquitin-mediated proteolysis: Cancer-associated and transforming mutations stabilize myc
233. Signal transduction by the high-affinity GM-CSF receptor: Two distinct cytoplasmic regions of the common β subunit responsible for different signalling
234. Embryonic lethality resulting from disruption of both N-myc alleles in mouse zygotes
235. Defects of embryonic organogenesis resulting from targeted disruption of the N-myc gene in the mouse
236. Dynamic expression of the myc protooncogene in midgestation mouse embryos
237. The role of c-myc in cellular growth control
238. Ink4a/arf mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
239. An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast repressor SIN3
240. Repression by the mad (Mxi1)-sin3 complex
241. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth
242. Drosophila Myc is oncogenic in mammalian cells and plays a role in the diminutive phenotype
243. Control of cell growth by c-Myc in the absence of cell division
244. Ras enhances Myc protein stability
245. Identification of positively and negatively acting elements regulating expression of the E2f2 gene in response to cell growth signals
246. Can ends justify the means? Telomeres and the mechanisms of replicafive senescence and immortalization in mammalian cells
247. Cell cycle regulation of the c-Myc transcriptional activation domain
248. Essential role for Max in early embryonic growth and development
249. IL-2 and EGF receptors stimulate the haematopoietic cell cycle via different signaling pathways: Demonstration of a novel role for c-myc
250. A unique glucose-dependent apoptotic pathway induced by c-myc
251. c-Myc transactivation of LDH-A: Implications for tumor metabolism and growth
252. Stabilization of c-myc protein in human glioma cells
253. Formation of α-pal/max heterodimers synergistically activates the eif2-α promoter
254. Inhibition of transcriptional regulator Yin-Yang-1 by association with c-Myc
255. Proliferative and metabolic capacity of rat embryo fibroblasts immortalized by c-myc depends on cellular age at oncogenic transfection
256. The leucine zipper of c-Myc is required for full inhibition of erythroleukemia differentiation
257. Distinct DNA binding preferences for the c-Myc/Max and Max/Max dimers
258. Identification and characterization of specific DNA-binding complexes containing members of the myc/max/mad network of transcriptional regulators
259. Potentiation of growth factor activity by exogenous c-myc expression
260. Design and properties of a myc derivative that efficiently homodimerizes
261. Control of c-myc regulation in normal and neoplastic cells
262. Enhanced translation and increased turnover of c-myc proteins occur during differentiation of murine erythroleukemia cells
263. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop
264. 1 cyclin-cdk complexes
265. Differential responsiveness of myc- and ras-transfected cells to growth factors: Selective stimulation of myctransfected cells by epidermal growth factor
266. Characterization of a transcription factor involved in mother cell specific transcription of the yeast HO gene
267. Definition of regions in human c-myc that are involved in transformation and nuclear localization
268. c-myc protein synthesis is initiated from the internal ribosome entry segment during apoptosis
269. c-myc 5′ untranslated region contains an internal ribosome entry segment
270. Novel primitive lymphoid tumors induced in transgenic mice by cooperation between myc and bcl-2
271. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p
272. The effect of alterations in myc gene expression on B-cell development in the bursa of Fabricius
273. Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene
274. Outer mitochondrial membrane permeability can regulate coupled respiration and cell survival
275. Expression of the mad gene during cell differentiation in vivo and its inhibition of cell growth in vitro
276. Binding of TAFs to core elements directs promoter selectivity by RNA polymerase II
277. c-myc down-regulates class I HLA expression in human melanomas
278. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer
279. RPD3 encodes a second factor required to achieve maximum positive and negative transcriptional states in Saccharomyces cerevisiae
280. RPD1 (SIN3/UMF4) is required for maximal activation and repression of diverse yeast genes
281. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1
282. Transition of localization of the N-Myc protein from nucleus to cytoplasm in differentiating neurons
283. c-myc/max heterodimers bind cooperatively to the E-box sequences located in the first intron of the rat ornithine decarboxylase (odc) gene
284. The Saccharomyces cerevisiae SIN3 gene, a negative regulator of HO, contains four paired amphipathic helix motifs
285. Transcriptional repression in Saccharomyces cerevisiae by a SIN3-LexA fusion protein
286. Myc activates telomerase
287. MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells
288. Translational induction of the c-myc oncogene via activation of the frap/tor signalling pathway
289. Direct activation of TERT transcription by c-MYC
290. Coordinated regulation of iron-controlling genes H-ferritin and IRP2, by c-MYC
291. Transactivation-defective c-MycS retains the ability to regulate proliferation and apoptosis
292. Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3
293. A Drosophila RNA helicase gene, pitchoune, is required for cell growth and proliferation and is a potential target of d-Myc
294. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites
295. Direct association of YY-1 with c-myc and the E-box binding protein in regulation of glycophorin gene expression
296. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization